267 related articles for article (PubMed ID: 27052171)
1. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
[TBL] [Abstract][Full Text] [Related]
2. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
eNeuro; 2015; 2(6):. PubMed ID: 26693177
[TBL] [Abstract][Full Text] [Related]
3. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin.
Sundberg M; Tochitsky I; Buchholz DE; Winden K; Kujala V; Kapur K; Cataltepe D; Turner D; Han MJ; Woolf CJ; Hatten ME; Sahin M
Mol Psychiatry; 2018 Nov; 23(11):2167-2183. PubMed ID: 29449635
[TBL] [Abstract][Full Text] [Related]
4. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
[TBL] [Abstract][Full Text] [Related]
5. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
[TBL] [Abstract][Full Text] [Related]
6. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
[TBL] [Abstract][Full Text] [Related]
7. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
9. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
10. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
11. Tubers from patients with tuberous sclerosis complex are characterized by changes in microtubule biology through ROCK2 signalling.
Ferrer I; Mohan P; Chen H; Castellsague J; Gómez-Baldó L; Carmona M; García N; Aguilar H; Jiang J; Skowron M; Nellist M; Ampuero I; Russi A; Lázaro C; Maxwell CA; Pujana MA
J Pathol; 2014 Jul; 233(3):247-57. PubMed ID: 24604753
[TBL] [Abstract][Full Text] [Related]
12. Establishment of Tsc2‑deficient rat embryonic stem cells.
Ito Y; Kawano H; Kanai F; Nakamura E; Tada N; Takai S; Horie S; Arai H; Kobayashi T; Hino O
Int J Oncol; 2015 May; 46(5):1944-52. PubMed ID: 25738543
[TBL] [Abstract][Full Text] [Related]
13. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors].
Zitterbart K
Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
[TBL] [Abstract][Full Text] [Related]
14. Abnormal Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Partially Mimicked Development of TSC2 Neurological Abnormalities.
Li Y; Cao J; Chen M; Li J; Sun Y; Zhang Y; Zhu Y; Wang L; Zhang C
Stem Cell Reports; 2017 Apr; 8(4):883-893. PubMed ID: 28344003
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex.
DiMario FJ; Sahin M; Ebrahimi-Fakhari D
Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
[TBL] [Abstract][Full Text] [Related]
17. High glucose concentrations mask cellular phenotypes in a stem cell model of tuberous sclerosis complex.
Rocktäschel P; Sen A; Cader MZ
Epilepsy Behav; 2019 Dec; 101(Pt B):106581. PubMed ID: 31761686
[TBL] [Abstract][Full Text] [Related]
18. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
20. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
